Harvard Bioscience, Inc.
Harvard Bioscience, Inc. (Nasdaq: HBIO) develops, manufactures and sells life-science instruments, consumables, software and services for research, drug and therapy discovery, bioproduction and preclinical testing. Its customers include pharmaceutical and biotechnology companies, contract research organizations,… From the company’s description.
Over the twelve months to Jun 30, 2026, Harvard Bioscience, Inc. reported revenue of $87.81M, down 1.1% from a year earlier, and a net loss of $10.41M. Its operating margin was −0.3%, and operations generated $0.65M in cash. In fiscal 2025, it reported revenue of $86.55M, down 8.1% from fiscal 2024, and a net loss of $56.70M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Harvard Bioscience, Inc. does
In the company’s own words
Harvard Bioscience, Inc. (Nasdaq: HBIO) develops, manufactures and sells life-science instruments, consumables, software and services for research, drug and therapy discovery, bioproduction and preclinical testing. Its customers include pharmaceutical and biotechnology companies, contract research organizations, universities, hospitals and government laboratories, served through direct sales and distributors worldwide. The company organizes its products into two families: Cellular and Molecular (CMT), which supports molecular, cellular, organ and organoid research and accounted for 46% of 2025 revenue; and Preclinical, which provides systems for physiological data collection and analysis in drug research and development and accounted for 54%. Third-party product distribution also contributed 13% of revenue in 2025. Brands include Harvard Apparatus, BTX, HEKA, KD Scientific, Warner, DSI, Panlab and Buxco. Founded as Harvard Apparatus in 1901, the company expanded into preclinical testing through its 2018 acquisition of Data Sciences International. It had 339 employees as of December 31, 2025. Its website is www.harvardbioscience.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- HOLLISTON, MA
- Fiscal year end
- December
- CIK
- 1123494
- SIC
- 3826
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Harvard Bioscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Harvard Bioscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Harvard Bioscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Harvard Bioscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Harvard Bioscience, Inc.'s last four quarterly filings that the numbers alone won't show?”